




Methods in Cell Biology • Volume 77

# THE ZEBRAFISH: 2<sup>ND</sup> EDITION GENETICS, GENOMICS AND INFORMATICS



Edited by

H. William Detrich, III • Monte Westerfield • Leonard I. Zon

# Methods in Cell Biology

**VOLUME 77**

*The Zebrafish: Genetics, Genomics, and Informatics*

## **Series Editors**

**Leslie Wilson**

Department of Molecular, Cellular and Developmental Biology  
University of California  
Santa Barbara, California

**Paul Matsudaira**

Whitehead Institute for Biomedical Research  
Department of Biology  
Division of Biological Engineering  
Massachusetts Institute of Technology  
Cambridge, Massachusetts

---

---

# Methods in Cell Biology

---

**VOLUME 77**

*The Zebrafish: Genetics, Genomics, and Informatics*

Edited by

**H. William Detrich, III**

Department of Biology  
Northeastern University  
Boston, Massachusetts

**Monte Westerfield**

Department of Biology  
University of Oregon  
Eugene, Oregon

**Leonard I. Zon**

Division of Hematology/Oncology  
Children's Hospital Boston  
Boston, Massachusetts



AMSTERDAM • BOSTON • HEIDELBERG • LONDON  
NEW YORK • OXFORD • PARIS • SAN DIEGO  
SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Elsevier Academic Press  
525 B Street, Suite 1900, San Diego, California 92101-4495, USA  
84 Theobald's Road, London WC1X 8RR, UK

This book is printed on acid-free paper. ∞

Copyright © 2004, Elsevier Inc. All Rights Reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the Publisher.

The appearance of the code at the bottom of the first page of a chapter in this book indicates the Publisher's consent that copies of the chapter may be made for personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center, Inc. ([www.copyright.com](http://www.copyright.com)), for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Copy fees for pre-2004 chapters are as shown on the title pages. If no fee code appears on the title page, the copy fee is the same as for current chapters. 0091-679X/2004 \$35.00

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone: (+44) 1865 843830, fax: (+44) 1865 853333, E-mail: [permissions@elsevier.com.uk](mailto:permissions@elsevier.com.uk). You may also complete your request on-line via the Elsevier homepage (<http://elsevier.com>), by selecting "Customer Support" and then "Obtaining Permissions."

For all information on all Academic Press publications  
visit our Web site at [www.academicpress.com](http://www.academicpress.com)

ISBN: 0-12-564172-9

PRINTED IN THE UNITED STATES OF AMERICA  
04 05 06 07 08 9 8 7 6 5 4 3 2 1

---

---

# CONTENTS

Contributors	xv
Preface	xxiii
Dedication	xxv

## **PART I Forward and Reverse Genetics**

### **1. Retroviral-Mediated Insertional Mutagenesis in Zebrafish**

*Adam Amsterdam and Nancy Hopkins*

I. Introduction	3
II. Mutagenesis	5
III. Cloning the Mutated Genes	8
IV. Future Directions	14
References	18

### **2. Genetic Screens for Maternal-Effect Mutations**

*Francisco Pelegri and Mary C. Mullins*

I. Introduction	22
II. Strategies for Maternal-Effect Screens	23
III. Selection of Lines for Genetic Screens	33
IV. Recovery and Maintenance of Maternal-Effect Mutations	37
V. Mapping Maternal-Effect Mutations	41
VI. Solutions, Materials, and Protocols	44
VII. Conclusions	48
References	49

### **3. Behavioral Screening Assays in Zebrafish**

*Michael B. Orger, Ethan Gahtan, Akira Muto, Patrick Page-McCaw, Matthew C. Smear, and Herwig Baier*

I. Introduction	53
II. General Considerations	54

III. Behavioral Assays	56
IV. Conclusions	66
References	66
4. Target-Selected Gene Inactivation in Zebrafish	
<i>Erno Wienholds and Ronald H. A. Plasterk</i>	
I. Introduction	70
II. Gene Targeting Strategies	71
III. Target-Selected Mutagenesis in Zebrafish	75
IV. Discussion	83
V. Materials and Methods	85
References	87
5. A High-Throughput Method for Identifying <i>N</i> -Ethyl- <i>N</i> -Nitrosourea (ENU)-Induced Point Mutations in Zebrafish	
<i>Bruce W. Draper, Claire M. McCallum, Jennifer L. Stout, Ann J. Slade, and Cecilia B. Moens</i>	
I. Introduction	92
II. Rationale for Reverse Genetics in Zebrafish	95
III. Rationale for Using the CEL1 Assay to Detect Induced Mutations	96
IV. Rationale for Generating a Cryopreserved Mutant Library	98
V. Method of <i>N</i> -Ethyl- <i>N</i> -Nitrosourea (ENU) Mutagenesis and Rearing of F <sub>1</sub> Founder Fish	98
VI. Generating a Cryopreserved Mutant Library	99
VII. Isolating Genomic DNA	102
VIII. Choosing Fragments to Screen	104
IX. CEL1 Endonuclease Assay	104
X. Recovery of Mutations from Cryopreserved Sperm	109
XI. Materials Cost Estimate	110
References	111
6. Production of Zebrafish Germline Chimeras by Using Cultured Embryonic Stem (ES) Cells	
<i>Lianchun Fan, Jennifer Crodian, and Paul Collodi</i>	
I. Introduction	113
II. Methods	114
III. Reagents	117
IV. Future Directions	118
References	118

<b>7. Nonconventional Antisense in Zebrafish for Functional Genomics Applications</b>	
<i>Stephen C. Ekker</i>	
I. Introduction	121
II. General Use of Nonconventional Antisense Tools in Zebrafish	123
III. Use of Morpholinos (MOs) as Antisense Tools in Zebrafish	125
IV. Comparison of MO-Based Screening Success to Mutational Methods	133
References	134
<b>8. Downregulation of Gene Expression with Negatively Charged Peptide Nucleic Acids (PNAs) in Zebrafish Embryos</b>	
<i>Eric Wickstrom, Karen A. Urtishak, Michael Choob, Xiaobing Tian, Nitzan Sternheim, Laura M. Cross, Amy Rubinstein, and Steven A. Farber</i>	
I. Introduction	138
II. Materials and Methods	143
III. Results	146
IV. Discussion	155
V. Summary	156
References	156
<b>9. Photo-Mediated Gene Activation by Using Caged mRNA in Zebrafish Embryos</b>	
<i>Hideki Ando, Toshiaki Furuta, and Hitoshi Okamoto</i>	
I. Introduction	160
II. Synthesis of Bhc-Caged mRNA	161
III. Microinjection of the Bhc-Caged mRNA	165
IV. Uncaging by Illumination of UV Light	167
V. Titration of Caging Efficiency	168
VI. Injection of Dimethyl Sulfoxide (DMSO) Solution of Caged mRNA	170
References	170
<b>10. Current Status of Medaka Genetics and Genomics</b>	
<i>The Medaka Genome Initiative (MGI)</i>	
<i>Manfred Scharl, Indrajit Nanda, Mariko Kondo, Michael Schmid, Shuichi Asakawa, Takashi Sasaki, Nobuyoshi Shimizu, Thorsten Henrich, Joachim Wittbrodt, Makoto Furutani-Seiki, Hisato Kondoh, Heinz Himmelbauer, Yunhan Hong, Akihiko Koga, Masaru Nonaka, Hiroshi Mitani, and Akihiro Shima</i>	
I. Introduction	174
II. Current Status of Medaka Genetics	175
III. Current Status of Medaka Genomics	186
IV. Other Progress	193

V. Internet Web Sites Relevant to Medaka Resources and Databases	193
References	194
<b>11. Transgenesis and Gene Trap Methods in Zebrafish by Using the <i>Tol2</i> Transposable Element</b>	
<i>Koichi Kawakami</i>	
I. Introduction	201
II. Transgenesis by Using the <i>Tol2</i> Transposable Element in Zebrafish	203
III. A Gene Trap Approach that Uses the <i>Tol2</i> Transposon System in Zebrafish	210
IV. Summary and Perspectives	219
References	220
<b>PART II The Zebrafish Genome and Mapping Technologies</b>	
<b>12. The Zebrafish Genome Project: Sequence Analysis and Annotation</b>	
<i>Kerstin Jekosch</i>	
I. Introduction	225
II. Automated Annotation of Whole Genome Shotgun (WGS) Assemblies	227
III. Clone-by-Clone Analysis and Annotation	230
IV. The Sanger Zebrafish Web Services	234
V. Future Releases	238
References	238
<b>13. Molecular Cytogenetic Methodologies and a Bacterial Artificial Chromosome (BAC) Probe Panel Resource for Genomic Analyses in Zebrafish</b>	
<i>Charles Lee and Amanda Smith</i>	
I. Introduction	241
II. Methods	242
III. First-Generation Zebrafish BAC Probe Panel	248
References	254
<b>14. Automated Analysis of Conserved Syntenies for the Zebrafish Genome</b>	
<i>John Postlethwait, Victor Ruotti, Michael J. Carvan, and Peter J. Tonellato</i>	
I. Introduction	256
II. The Conservation of Zebrafish and Mammalian Genomes	256
III. Using Genome Conservation in Zebrafish Research	258

IV. Genomic Connections Between Zebrafish and Tetrapods Facilitate Disease Research	260
V. Bioinformatic Approaches to Automating Zebrafish Connections and Comparative Maps	264
VI. A Conserved Syntenic Map for Zebrafish: Preliminary Results	266
VII. Conclusion	267
References	268
15. Update of the Expressed Sequence Tag (EST) and Radiation Hybrid Panel Projects	
<i>Yi Zhou</i>	
I. Expressed Sequence Tag (EST) Projects	274
II. Radiation Hybrid (RH) Panel Project	277
III. Future Directions	291
References	292
16. Bacterial Artificial Chromosome (BAC) Clones and the Current Clone Map of the Zebrafish Genome	
<i>Romke Koch, Gerd-Jörg Rauch, Sean Humphray, Robert Geisler, and Ronald Plasterk</i>	
I. Introduction	296
II. Physical Map of Fingerprinted Clones	296
III. Screening Methods and Utilization of the Current Zebrafish Clone Map	300
IV. Example: Discovery of the Zebrafish <i>dicer1</i> Gene	302
References	304
17. The Zon Laboratory Guide to Positional Cloning in Zebrafish	
<i>Nathan Bahary, Alan Davidson, David Ransom, Jennifer Shepard, Howard Stern, Nikolaus Trede, Yi Zhou, Bruce Barut, and Leonard I. Zon</i>	
I. Introduction	306
II. Mapping Strains	306
III. Families and Genetic Markers	307
IV. Crosses for Line Maintenance and Mapping	307
V. Preparation of the DNA	309
VI. Mapping Genes	310
VII. Overgo Strategy for Rapidly Doing Chromosomal Walks and Positional Cloning	317
VIII. Protocol for Overgo Probing of High-Density Filters	318
IX. General Flow of Information from the Radiation Hybrid Panel Maps, the Sanger Institute Sequencing Project, and Fingerprinting the BACs	321
X. Syteny Between Human, Zebrafish, and <i>Fugu</i> Genomes	325

XI. Proving a Candidate Gene Is Responsible for the Mutant Phenotype	326
XII. Morpholinos	327
References	328

### **PART III Transgenesis**

<b>18. Lessons from Transgenic Zebrafish Expressing the Green Fluorescent Protein (GFP) in the Myeloid Lineage</b>	
<i>Karl Hsu, A. Thomas Look, and John P. Kanki</i>	
I. Introduction	334
II. Myeloid Cells in Zebrafish	334
III. Expression of <i>pu.1</i> in Myeloid Development	335
IV. Analysis of the Zebrafish <i>pu.1</i> Locus	336
V. Germline Expression of Enhanced Green Fluorescent Protein (EGFP) Under Control of the Zebrafish <i>pu.1</i> Promoter	338
VI. Conclusions	345
References	346
<b>19. Sleeping Beauty Transposon for Efficient Gene Delivery</b>	
<i>Spencer Hermanson, Ann E. Davidson, Sridhar Sivasubbu, Darius Balciunas, and Stephen C. Ekker</i>	
I. Introduction	349
II. Transgenesis Constructs	350
III. Microinjection of the Zebrafish Embryo	351
IV. Raising Injected Embryos	355
V. Identifying Transgenic Founders	356
VI. Visualizing Fluorescent Reporters	357
VII. Molecular Characterization of the Transposon Integration Site	358
References	361
<b>20. Transgene Manipulation in Zebrafish by Using Recombinases</b>	
<i>Jie Dong and Gary W. Stuart</i>	
I. Introduction	363
II. Recombinase-Mediated Transgene Exchange and Mobilization	367
III. Summary and Conclusion	375
References	376

<b>21.</b>	Highly Efficient Zebrafish Transgenesis Mediated by the Meganuclease I-SceI <i>Clemens Grabher, Jean-Stephane Joly, and Joachim Wittbrodt</i>	
	I. Introduction	381
	II. Transgenesis by Meganucleases	386
	References	398
<b>22.</b>	Cloning Zebrafish by Nuclear Transfer <i>Bensheng Ju, Haigen Huang, Ki-Young Lee, and Shuo Lin</i>	
	I. Introduction	403
	II. Recipes for Cell Culture and Nuclear Transfer	404
	III. Cell Culture	404
	IV. Nuclear Transfer	405
	V. Summary of Nuclear Transfer	408
	VI. Potential Applications of Zebrafish Cloning	409
	References	410

## **PART IV Informatics and Comparative Genomics**

<b>23.</b>	Data Mining the Zebrafish Genome <i>Lynn M. Schriml and Judy Sprague</i>	
	I. Introduction	415
	II. National Center for Biotechnology Information (NCBI) Tools, Resources, and Data Sets	416
	III. Zebrafish Information Network (ZFIN)	428
	IV. Tutorial	433
	References	437
<b>24.</b>	The Zebrafish DVD Exchange Project: A Bioinformatics Initiative <i>Mark S. Cooper, Greg Sommers-Herivel, Cara T. Poage, Matthew B. McCarthy, Bryan D. Crawford, and Carey Phillips</i>	
	I. Introduction	440
	II. Economic Aspects of Visual Bioinformatics	440
	III. Building Infrastructures to Access Images	442
	IV. Prior Experiences with Visual Data Dissemination (Mark Cooper)	443
	V. Goals of the Zebrafish DVD Exchange Project	445
	VI. Production of the Compact Disc (CD) Set: “Zebrafish: The Living Laboratory” (Greg Sommers-Herivel)	447
	VII. Visual Bioinformatics and Databases	451

VIII. Internet2	452
IX. Hyper Text Markup Language (HTML) and eXtensible Markup Language XML (Bryan Crawford)	453
X. Virtual Reality and Data Visualization Tools (Carey Phillips)	454
XI. Summary	456
References	457
25. Comparative Genomics—An Application for Positional Cloning of the <i>weissherbst</i> Mutant	
<i>Anhua Song and Yi Zhou</i>	
I. Introduction	459
II. Resources for Comparative Genomics Studies	460
III. An Example of Using Comparative Genomic Resources in a Positional Cloning Project	461
References	473
26. Comparative Genomics in Erythropoietic Gene Discovery: Synergisms Between the Antarctic Icefishes and the Zebrafish	
<i>H. William Detrich, III and Donald A. Yergeau</i>	
I. Introduction	476
II. Representational Difference Analysis (RDA) Protocol	477
III. Analysis of Unidentified RDA Contigs	485
IV. Isolation of Full-Length cDNAs Corresponding to RDA Products	493
V. Model Hopping: Functional Analysis of the Zebrafish Ortholog of the Novel Antarctic Fish Gene <i>bloodthirsty</i>	498
VI. General Considerations	500
References	501
27. Spatial and Temporal Expression of the Zebrafish Genome by Large-Scale <i>In Situ</i> Hybridization Screening	
<i>Bernard Thisse, Vincent Heyer, Aline Lux, Violaine Alunni, Agnès Degrave, Iban Seiliez, Johanne Kirchner, Jean-Paul Parkhill, and Christine Thisse</i>	
I. Introduction and Goals	506
II. Preparation of Antisense Digoxigenin (DIG)-Labeled RNA Probes	506
III. Preparation of Embryos	508
IV. Reagents and Buffers for <i>In Situ</i> Hybridization	509
V. <i>In Situ</i> Hybridization Protocol	510
VI. Double <i>In Situ</i> Protocol	514

VII. Recording Results	517
VIII. Concluding Remarks	517
References	519
28. Design, Normalization, and Analysis of Spotted Microarray Data	
<i>F. B. Pichler, M. A. Black, L. C. Williams, and D. R. Love</i>	
I. Introduction	522
II. Design of Microarray Experiments	522
III. Array Preprocessing	530
IV. Analysis of Microarray Experiments	535
V. Discussion	540
References	542
29. Comparative Genomics, <i>cis</i> -Regulatory Elements, and Gene Duplication	
<i>Allan Force, Cooduvalli Shashikant, Peter Stadler, and Chris T. Amemiya</i>	
I. Introduction	545
II. Comparative Genomics and Identification of <i>cis</i> -Regulatory Elements (CREs)	546
III. Duplicated Genomes, Duplicated Genes	552
References	556
<b>PART V Infrastructure</b>	
30. Zebrafish Facilities for Small and Large Laboratories	
<i>Bill Trevarrow</i>	
I. Introduction	566
II. Zebrafish Biology	568
III. Fish Housing	569
IV. Quarantining	586
V. Injections	587
VI. Mutagenesis Room	587
VII. Treating Outflow	588
VIII. Disposing of the Dead	588
IX. Disease Prevention	589
X. Cleaning	590
XI. Human Safety	590
References	591

<b>31. A Nursery that Improves Zebrafish Fry Survival</b>	
<i>Peter Cattin and Phil Crosier</i>	
I. Introduction	593
II. General Methods for Raising Embryos and Larvae	594
III. A Nursery that Improves Fry Survival	594
References	598
<b>32. Genetic Backgrounds, Standard Lines, and Husbandry of Zebrafish</b>	
<i>Bill Trevarrow and Barrie Robison</i>	
I. Introduction	599
II. Nomenclature and Definitions	602
III. Goals for Line Use	603
IV. Breeding Strategies	604
V. Cryopreservation	612
VI. Monitoring and Response	613
VII. Distribution	614
VIII. Summary and Recommendations	614
References	615
<b>33. Common Diseases of Laboratory Zebrafish</b>	
<i>Jennifer L. Matthews</i>	
I. Introduction	617
II. Diagnostic Evaluation	618
III. Common Diseases of Laboratory Zebrafish	618
IV. Zoonosis	640
References	641
<b>34. Zebrafish Sperm Cryopreservation</b>	
<i>Stéphane Berghmans, John P. Morris IV, John P. Kanki, and A. Thomas Look</i>	
I. Introduction: Benefits of Zebrafish Sperm Cryopreservation	645
II. Critical Variables Affecting Sperm Cryopreservation	646
III. Zebrafish Sperm Cryopreservation with <i>N,N</i> -Dimethylacetamide	650
IV. Future Directions	656
References	658
Index	661
Volumes in Series	679

---

---

## CONTRIBUTORS

*Numbers in parentheses indicate the pages on which the authors' contributions begin.*

**Violaine Alunni** (505), Institut de Génétique et de Biologie Moléculaire et Cellulaire, UMR 7104 CNRS/INSERM/ULP, BP 10142, CU de Strasbourg, 67404 Illkirch Cedex, France

**Chris T. Amemiya** (545), Molecular Genetics Program, Benaroya Research Institute, Seattle, Washington 98101

**Adam Amsterdam** (3), Center for Cancer Research and Department of Biology, Massachusetts Institute for Technology, Cambridge, Massachusetts 01239

**Hideki Ando** (159), Laboratory for Developmental Gene Regulation, Brain Science Institute, RIKEN (The Institute of Physical and Chemical Research), Saitama 351-0198, Japan and CREST (Core Research for Evolutional Science and Technology), Japan Science and Technology Corporation (JST), Chuo-ku, Tokyo 103-0027, Japan

**Shuichi Asakawa** (173), Department of Molecular Biology, Keio University School of Medicine, Tokyo 160-8582, Japan

**Nathan Bahary** (305), Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts 02115

**Herwig Baier** (49), Department of Physiology, University of California, San Francisco, San Francisco, California 94143

**Darius Balciunas** (349), The Arnold and Mabel Beckman Center for Transposon Research, Department of Genetics, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, Minnesota 55455

**Bruce Barut** (305), Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts 02115

**Stéphane Berghmans** (645), Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115

**M. A. Black** (521), Department of Statistics, University of Auckland, 1001 Auckland, New Zealand

**Michael J. Carvan** (255), Great Lakes WATER Institute, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin 5320

**Peter Cattin** (593), Department of Molecular Medicine and Pathology, School of Medical Sciences, The University of Auckland, Auckland, New Zealand

**Michael Choob** (137), Active Motif, Carlsbad, California 92008

**Paul Collodi** (113), Department of Animal Sciences, Purdue University, West Lafayette, Indiana 47907

- Mark S. Cooper** (439), Department of Biology and Center for Developmental Biology, University of Washington, Seattle, Washington 98195
- Bryan D. Crawford** (439), Department of Biology, University of Alberta, Edmonton, Alberta, Canada T6G 2E9
- Jennifer Crodian** (113), Department of Animal Sciences, Purdue University, West Lafayette, Indiana 47907
- Phil Crosier** (593), Department of Molecular Medicine and Pathology, School of Medical Sciences, The University of Auckland, Auckland, New Zealand
- Laura M. Cross** (137), Zygogen, Atlanta, Georgia 30303
- Alan Davidson** (305), Howard Hughes Medical Institute, Division of Hematology/Oncology, Children's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02115
- Ann E. Davidson** (349), The Arnold and Mabel Beckman Center for Transposon Research, Department of Genetics, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, Minnesota 55455
- Agnès Degrave** (505), Institut de Génétique et de Biologie Moléculaire et Cellulaire, UMR 7104 CNRS/INSERM/ULP, BP 10142, CU de Strasbourg, 67404 Illkirch Cedex, France
- H. William Detrich, III** (475), Department of Biology, Northeastern University, Boston, Massachusetts 02115
- Jie Dong** (363), Department of Life Sciences, Indiana State University, Terre Haute, Indiana 47809
- Bruce W. Draper** (91), Howard Hughes Medical Institute and Division of Basic Science, Fred Hutchinson Cancer Research Institute, Seattle, Washington 98109
- Stephen C. Ekker** (121, 349), The Arnold and Mabel Beckman Center for Transposon Research, Department of Genetics, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, Minnesota 55455
- Lianchun Fan** (113), Department of Animal Sciences, Purdue University, West Lafayette, Indiana 47907
- Steven A. Farber** (137), Department of Microbiology & Immunology and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107
- Allan Force** (545), Molecular Genetics Program, Benaroya Research Institute, Seattle, Washington 98101
- Toshiaki Furuta** (159), Department of Biomolecular Science, Toho University, Funabashi Chiba 274-8510, Japan and PREST (Precursory Research for Embryonic Science and Technology), Japan Science and Technology Corporation (JST), Tokyo 103-0072, Japan
- Makoto Furutani-Seiki** (173), ERATO, 14 Yoshida-kawaramachi, Sakyo-ku, Kyoto 606-8305, Japan
- Ethan Gahtan** (49), Department of Physiology, University of California, San Francisco, San Francisco, California 94143 and Department of Biology, Rennselaer Polytechnic Institute, Troy, New York 12180
- Robert Geisler** (295), Max-Planck-Institut für Entwicklungsbiologie, D-72076 Tübingen, Germany

- Clemens Grabher** (381), Developmental Biology Program, European Molecular Biology Laboratory (EMBL), 69117-Heidelberg, Germany
- Thorsten Henrich** (173), Developmental Biology Programme, EMBL-Heidelberg, D-69012 Heidelberg, Germany
- Spencer Hermanson** (349), The Arnold and Mabel Beckman Center for Transposon Research, Department of Genetics, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, Minnesota 55455
- Vincent Heyer** (505), Institut de Génétique et de Biologie Moléculaire et Cellulaire, UMR 7104 CNRS/INSERM/ULP, BP 10142, CU de Strasbourg, 67404 Illkirch Cedex, France
- Heinz Himmelbauer** (173), Max-Planck-Institute of Molecular Genetics, D-14195 Berlin, Germany
- Yunhan Hong** (173), Department of Biological Sciences, National University of Singapore, Singapore 117543
- Nancy Hopkins** (1), Center for Cancer Research and Department of Biology, Massachusetts Institute for Technology, Cambridge, Massachusetts 01239
- Karl Hsu** (333), Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115
- Haigen Huang** (403), Department of Molecular, Cellular, and Developmental Biology, University of California Los Angeles, Los Angeles, California 90095
- Sean Humphray** (295), Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, United Kingdom
- Kerstin Jekosch** (225), Wellcome Trust Sanger Institute, Cambridge CB10 1SA, United Kingdom
- Jean-Stephane Joly** (381), INRA, Institute de Neurobiologie A. Fessard, CNRS, 91198 Gif-Sur-Yvette, France
- Bensheng Ju** (403), Department of Molecular, Cellular, and Developmental Biology, University of California Los Angeles, Los Angeles, California 90095
- John P. Kanki** (333, 645), Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
- Koichi Kawakami** (201), Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka 411-8540, Japan
- Johanne Kirchner** (505), Institut de Génétique et de Biologie Moléculaire et Cellulaire, UMR 7104 CNRS/INSERM/ULP, BP 10142, CU de Strasbourg, 67404 Illkirch Cedex, France
- Romke Koch** (295), Hubrecht Laboratory, Uppsalalaan 8, 3584 CT Utrecht, The Netherlands
- Akihiko Koga** (173), Division of Biological Sciences, Graduate School of Science, Nagoya University, Nagoya 464-8602, Japan
- Mariko Kondo** (173), Biocenter, University of Wuerzburg, Am Hubland, D-97074 Wuerzburg, Germany
- Hisato Kondoh** (173), ERATO, 14 Yoshida-kawaramachi, Sakyo-ku, Kyoto 606-8305, Japan

- Charles Lee** (241), Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts 02115
- Ki-Young Lee** (403), Department of Molecular, Cellular, and Developmental Biology, University of California Los Angeles, Los Angeles, California 90095
- Shuo Lin** (403), Department of Molecular, Cellular, and Developmental Biology, University of California Los Angeles, Los Angeles, California 90095
- A. Thomas Look** (333, 645), Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
- D. R. Love** (521), Molecular Genetics and Development Group, School of Biological Sciences, University of Auckland, 1001 Auckland, New Zealand
- Aline Lux** (505), Institut de Génétique et de Biologie Moléculaire et Cellulaire, UMR 7104 CNRS/INSERM/ULP, BP 10142, CU de Strasbourg, 67404 Illkirch Cedex, France
- Jennifer L. Matthews** (617), The Zebrafish International Resource Center, University of Oregon, Eugene, Oregon 97403
- Claire M. McCallum** (91), Anawah, Inc., Seattle, Washington 98104
- Matthew B. McCarthy** (439), Department of Biology and Center for Developmental Biology, University of Washington, Seattle, Washington 98195
- Hiroshi Mitani** (173), Department of Integrated Biosciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa City, Chiba 277-8562, Japan
- Cecilia B. Moens** (91), Howard Hughes Medical Institute and Division of Basic Science, Fred Hutchinson Cancer Research Institute, Seattle, Washington 98109
- John P. Morris IV** (645), Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
- Mary C. Mullins** (21), University of Pennsylvania, Department of Cell and Developmental Biology, Philadelphia, Pennsylvania 19104
- Akira Muto** (49), Department of Physiology, University of California, San Francisco, San Francisco, California 94143
- Indrajit Nanda** (173), Biocenter, University of Wuerzburg, Am Hubland, D-97074 Wuerzburg, Germany
- Masaru Nonaka** (173), Department of Biological Sciences, Graduate School of Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- Hitoshi Okamoto** (159), Laboratory for Developmental Gene Regulation, Brain Science Institute, RIKEN (The Institute of Physical and Chemical Research), Saitama 351-0198, Japan and CREST (Core Research for Evolutional Science and Technology), Japan Science and Technology Corporation (JST), Tokyo 103-0027, Japan
- Michael B. Orger** (49), Department of Physiology, University of California, San Francisco, San Francisco, California 94143
- Patrick Page-McCaw** (49), Department of Physiology, University of California, San Francisco, San Francisco, California 94143 and Department of Biology, Rensselaer Polytechnic Institute, Troy, New York 12180

- Jean-Paul Parkhill** (505), Institut de Génétique et de Biologie Moléculaire et Cellulaire, UMR 7104 CNRS/INSERM/ULP, BP 10142, CU de Strasbourg, 67404 Illkirch Cedex, France
- Francisco Pelegri** (21), University of Wisconsin—Madison, Laboratory of Genetics, Madison, Wisconsin 53706
- Carey Phillips** (439), Department of Biology, Bowdoin College, Brunswick, Maine 04011
- F. B. Pichler** (521), Molecular Genetics and Development Group, School of Biological Sciences, University of Auckland, 1001 Auckland, New Zealand
- Ronald H. A. Plasterk** (69, 295), Hubrecht Laboratory, Center for Biomedical Genetics, Uppsalalaan 8, 3584 CT Utrecht, The Netherlands
- Cara T. Poage** (439), Department of Biology and Center for Developmental Biology, University of Washington Seattle, Washington 98195
- John Postlethwait** (255), Institute of Neuroscience, University of Oregon, Eugene, Oregon 97403
- David Ransom** (305), Division of Hematology/Oncology, Children's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02115
- Gerd-Jörg Rauch** (295), Max-Planck-Institut für Entwicklungsbiologie, Tübingen, Germany
- Barrie Robison** (599), Department of Biological Sciences, University of Idaho, Moscow, Idaho 83844
- Amy Rubinstein** (137), Zygogen, Atlanta, Georgia 30303
- Victor Ruotti** (255), Human & Molecular Genetics Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226
- Takashi Sasaki** (173), Department of Molecular Biology, Keio University School of Medicine, Tokyo 160-8582, Japan
- Manfred Schartl** (173), Biocenter, University of Wuerzburg, Am Hubland, D-97074 Wuerzburg, Germany
- Michael Schmid** (173), Biocenter, University of Wuerzburg, Am Hubland, D-97074 Wuerzburg, Germany
- Lynn M. Schriml** (415), National Center for Biotechnology Information (NCBI), National Institutes of Health, Bethesda, Maryland 20894
- Iban Seiliez** (505), Institut de Génétique et de Biologie Moléculaire et Cellulaire, UMR 7104 CNRS/INSERM/ULP, BP 10142, CU de Strasbourg, 67404 Illkirch Cedex, France
- Cooduvalli Shshikant** (545), College of Agricultural Sciences, The Pennsylvania State University, University Park, Pennsylvania 16802
- Jennifer Shepard** (305), Division of Hematology/Oncology, Children's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02115
- Akihiro Shima** (173), Department of Integrated Biosciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa City, Chiba 277-8562, Japan

- Nobuyoshi Shimizu** (173), Department of Molecular Biology, Keio University School of Medicine, Tokyo 160-8582, Japan
- Sridhar Sivasubbu** (349), The Arnold and Mabel Beckman Center for Transposon Research, Department of Genetics, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, Minnesota 55455
- Ann J. Slade** (91), Anawah, Inc., Seattle, Washington 98104
- Matthew C. Smear** (49), Department of Physiology, University of California, San Francisco, San Francisco, California 94143
- Amanda Smith** (241), Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115
- Greg Sommers-Herivel** (439), Department of Biology and Center for Developmental Biology, University of Washington Seattle, Washington 98195
- Anhua Song** (459), Children's Hospital Boston and Harvard Medical School, Boston, Massachusetts 02115
- Judy Sprague** (415), Zebrafish Information Network (ZFIN), University of Oregon, Eugene, Oregon 97403
- Peter Stadler** (545), Bioinformatics, Department of Computer Science, University of Leipzig, D-04103 Leipzig, Germany
- Howard Stern** (305), Division of Hematology/Oncology, Children's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02115
- Nitzan Sternheim** (137), Department of Developmental Biology, Stanford University, Stanford, California 94305
- Jennifer L. Stout** (91), Howard Hughes Medical Institute and Division of Basic Science, Fred Hutchinson Cancer Research Institute, Seattle, Washington 98109
- Gary W. Stuart** (363), Department of Life Sciences, Indiana State University, Terre Haute, Indiana 47809
- Bernard Thisse** (505), Institut de Génétique et de Biologie Moléculaire et Cellulaire, UMR 7104 CNRS/INSERM/ULP, BP 10142, CU de Strasbourg, 67404 Illkirch Cedex, France
- Christine Thisse** (505), Institut de Génétique et de Biologie Moléculaire et Cellulaire, UMR 7104 CNRS/INSERM/ULP, BP 10142, CU de Strasbourg, 67404 Illkirch Cedex, France
- Xiaobing Tian** (137), Department of Biochemistry & Molecular Pharmacology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107
- Peter J. Tonellato** (255), Human & Molecular Genetics Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226
- Nikolaus Trede** (305), Division of Hematology/Oncology, Children's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02115
- Bill Trevarrow** (565, 599), Institute of Neuroscience, University of Oregon, Eugene, Oregon 97403
- Karen A. Urtishak** (137), Department of Microbiology & Immunology and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107

- Eric Wickstrom** (137), Department of Biochemistry & Molecular Pharmacology, Department of Microbiology & Immunology, and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107
- Erno Wienholds** (69), Hubrecht Laboratory, Center for Biomedical Genetics, Uppsalalaan 8, 3584 CT Utrecht, The Netherlands
- L. C. Williams** (521), Molecular Genetics and Development Group, School of Biological Sciences, University of Auckland, 1001 Auckland, New Zealand
- Joachim Wittbrodt** (173, 381), Developmental Biology Program, European Molecular Biology Laboratory (EMBL), D-69012, Germany
- Donald A. Yergeau** (475), Department of Biology, Northeastern University, Boston, Massachusetts 02115
- Yi Zhou** (273, 305, 459), Division of Hematology/Oncology, Children's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02115
- Leonard I. Zon** (305), Howard Hughes Medical Institute, Division of Hematology/Oncology, Children's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02115

This Page Intentionally Left Blank

---

---

## PREFACE

Monte, Len, and I welcome you to two new volumes of *Methods in Cell Biology* devoted to *The Zebrafish: Cellular and Developmental Biology* and *Genetics, Genomics, and Informatics*. In the five years since publication of the first pair of volumes, *The Zebrafish: Biology* (Vol. 59) and *The Zebrafish: Genetics and Genomics* (Vol. 60), revolutionary advances in techniques have greatly increased the versatility of this system. At the Fifth Conference on *Zebrafish Development and Genetics*, held at the University of Wisconsin in 2003, it was clear that many new and compelling methods were maturing and justified the creation of the present volumes. The zebrafish community responded enthusiastically to our request for contributions, and we thank them for their tremendous efforts.

The new volumes present the post-2000 advances in molecular, cellular, and embryological techniques (Vol. 76) and in genetic, genomic, and bioinformatic methods (Vol. 77) for the zebrafish, *Danio rerio*. The latter volume also contains a section devoted to critical infrastructure issues. Overlap with the prior volumes has been minimized intentionally.

The first volume, *Cellular and Developmental Biology*, is divided into three sections: Cell Biology, Developmental and Neural Biology, and Disease Models. The first section focuses on microscopy and cell culture methodologies. New microscopic modalities and fluorescent reporters are described, the cell cycle and lipid metabolism in embryos are discussed, apoptosis assays are outlined, and the isolation and culture of stem cells are presented. The second section covers development of the nervous system, techniques for analysis of behavior and for screening for behavioral mutants, and methods applicable to the study of major organ systems. The volume concludes with a section on use of the zebrafish as a model for several diseases.

The second volume, *Genetics, Genomics, and Informatics*, contains five sections: Forward and Reverse Genetics, The Zebrafish Genome and Mapping Technologies, Transgenesis, Informatics and Comparative Genomics, and Infrastructure. In the first, forward-genetic (insertional mutagenesis, maternal-effects screening), reverse-genetic (antisense morpholino oligonucleotide and peptide nucleic acid gene knockdown strategies, photoactivation of caged mRNAs), and hybrid (target-selected screening for ENU-induced point mutations) technologies are described. Genetic applications of transposon-mediated transgenesis of zebrafish are presented, and the status of the genetics and genomics of *Medaka*, the honorary zebrafish, is updated. Section 2 covers the zebrafish genome project, the cytogenetics of zebrafish chromosomes, several methods for mapping zebrafish genes and mutations, and the recovery of mutated genes via positional cloning.

The third section presents multiple methods for transgenesis in zebrafish and describes the application of nuclear transfer for cloning of zebrafish. Section 4 describes bioinformatic analysis of the zebrafish genome and of microarray data, and emphasizes the importance of comparative analysis of genomes in gene discovery and in the elucidation of gene regulatory elements. The final section provides important, but difficult to find, information on small- and large-scale infrastructure available to the zebrafish biologist.

The attentive reader will have noticed that this Preface was drafted by the first editor, Bill Detrich, while he (I) was at sea leading the sub-Antarctic ICEFISH Cruise (International Collaborative Expedition to collect and study Fish Indigenous to Sub-antarctic Habitats; visit [www.icefish.neu.edu](http://www.icefish.neu.edu)). Wearing my second biological hat, I study the adaptational biology of Antarctic fish and use them as a system for comparative discovery of erythropoietic genes. Antarctic fish embryos generally hatch after six months of development, and they reach sexual maturity only after several years. Imagine attempting genetic studies on these organisms! My point is that the zebrafish system and its many advantages greatly inform my research on Antarctic fish, while at the same time I can move genes discovered by study of the naturally evolved, but very unusual, phenotypes of Antarctic fish into the zebrafish for functional analysis. We the editors emphasize that comparative strategies applied to multiple organisms, including the diverse fish taxa, are destined to play an increasing role in our understanding of vertebrate development.

We wish to express our gratitude to the series editors, Leslie Wilson and Paul Matsudaira, and the staff of Elsevier/Academic Press, especially Kristi Savino, for their diligent help, great patience, and strong encouragement as we developed these volumes.

H. William Detrich, III  
Monte Westerfield  
Leonard I. Zon

This volume is dedicated to Jose Campos-Ortega and Nigel Holder,  
departed colleagues whose wisdom and friendship will be missed  
by the zebra fish community

This Page Intentionally Left Blank

---

---

**PART I**

Forward and Reverse Genetics

This Page Intentionally Left Blank

---

---

## CHAPTER 1

# Retroviral-Mediated Insertional Mutagenesis in Zebrafish

**Adam Amsterdam and Nancy Hopkins**

Center for Cancer Research and Department of Biology  
Massachusetts Institute for Technology  
Cambridge, Massachusetts 01239

---

- I. Introduction
- II. Mutagenesis
  - A. Making Founder Fish That Transmit Proviral Inserts at High Frequency to Their F1 Progeny
  - B. Breeding and Screening for Mutations
- III. Cloning the Mutated Genes
  - A. Identifying the Mutagenic Insert
  - B. Cloning the Flanking Genomic DNA
  - C. Gene Identification
  - D. Phenotypic Consequence of Insertions
- IV. Future Directions
- References

---

---

---

## I. Introduction

Large-scale chemical mutagenesis screens have resulted in the isolation of thousands of mutations in hundreds of genes that affect zebrafish embryonic development (Driever *et al.*, 1996; Haffter *et al.*, 1996). These screens have used an alkylating agent, ethyl nitrosourea (ENU), to induce mutations, primarily by causing base pair substitutions. Approximately 100 of the genes disrupted by these mutations have been isolated till March 2004, primarily through a candidate gene approach and less frequently by pure positional cloning (Postlethwait and Talbot, 1997), and many other chapters in this volume are devoted to describing this. However, positional cloning remains arduous.

Insertional mutagenesis is an alternative to chemical mutagenesis in which exogenous DNA is used as the mutagen. Although insertional mutagenesis is usually less efficient than ENU, insertions serve as a molecular tag to aid in the isolation of the mutated genes. Several methods can be employed to insert DNA into the zebrafish genome, including DNA microinjection (Culp *et al.*, 1991; Stuart *et al.*, 1988), or microinjection of DNA aided by retroviral integrases (Ivics *et al.*, 1993) or a transposable element's transposase (Davidson *et al.*, 2003; Kawakami *et al.*, 2000; Raz *et al.*, 1997); reviews and updates on these methods can be found in other chapters in this volume. However, to date, by far the most efficient way to make a large number of insertions in the zebrafish genome is to use a pseudotyped retrovirus.

Retroviruses have an RNA genome and, on infection of a cell, reverse transcribe their genome to a DNA molecule, the provirus. The provirus integrates into a host cell chromosome, where it remains stable and is thus inherited by all the descendants of that cell. Replication-defective retroviral vectors, unlike nondefective retroviruses, are infectious agents that can integrate into host DNA, but whose genetic material lacks the coding sequences for the proteins required to make progeny virions. Retroviral vectors are made in split-genome packaging cells, in which the genome of the retroviral vector is expressed from one integrated set of viral sequences, whereas the retroviral genes required for packaging, infection, reverse transcription, and integration are expressed from another locus. The most widely used retroviral vectors have been derived from a murine retrovirus, the Moloney murine leukemia virus (MoMLV), resulting in replication-defective viruses that can be produced at very high titers. Initially, these retroviruses were only capable of infecting mammalian cells, but their host range can be expanded as described later.

Retroviruses have a host range, or tropism, which is frequently determined by their envelope protein, which recognizes and binds to some specific component, usually a protein, on the surface of the cell to be infected. Cell types that have an appropriate receptor can be infected by the retrovirus, whereas those that do not are refractory to infection. The host range of a virus can be changed by pseudotyping, a process in which virions acquire the genome and core proteins of one virus but the envelope protein of another. One way to enable this situation in split-genome packaging cells is to simply substitute the gene encoding the alternative envelope protein for the usual one. Although there is some specificity as to which envelope proteins can be pseudotyped with which viral genomes, one such combination that is particularly useful allows the MoMLV viral genomes and core proteins to be pseudotyped with the envelope glycoprotein (G-protein) of the vesicular stomatitis virus (VSV; Weiss *et al.*, 1974). VSV is a rhabdovirus that is apparently pantropic; it can infect cells of species as diverse as insects and mammals (Wagner, 1972). MoMLV vectors pseudotyped with VSV-G possess two qualities essential for their use in high-frequency germline transgenesis in zebrafish: the extended host range allows for the infection of

fish cells, and the VSV-G-pseudotyped virions are unusually stable, allowing viruses to be concentrated 1000-fold by centrifugation (Burns *et al.*, 1993).

When pseudotyped retroviral vectors are injected into zebrafish blastulae, many of the cells become independently infected, producing a mosaic organism in which different cells harbor proviral insertions at different chromosomal sites. When cells destined to give rise to the germ-line are infected, some proportion of the progeny of the injected fish will contain one or more insertions (Lin *et al.*, 1994). When a sufficiently high-titer virus is used, one can infect a very high proportion of the germline of injected fish (Gaiano *et al.*, 1996a). With very high-titer virus, on average, about 25–30 independent insertions can be inherited from a single founder, though any given insertion will only be present in about 3–20% of the offspring (Chen *et al.*, 2002; A. Amsterdam, unpublished data). However, the progeny are nonmosaic for the insertions and transmits them in a Mendelian fashion to 50% of then progeny. Furthermore, because more than one virus can infect a single cell, some germ cells contain multiple insertions, and thus offspring can be born with as many as 10–15 independently segregating insertions (Amsterdam *et al.*, 1999; Chen *et al.*, 2002; Gaiano *et al.*, 1996a). This remarkable transgenesis rate has made it possible to conduct an insertional mutagenesis screen, which has allowed isolation of hundreds of insertional mutants and rapid cloning of the mutated genes (Amsterdam *et al.*, 1999, 2004a; Golling *et al.*, 2002).

---

---

---

## II. Mutagenesis

To establish the frequency of mutagenesis with retroviral vectors in the zebrafish, we carried out a pilot screen in which we inbred more than 500 individual proviral insertions, one at a time, and screened for recessive phenotypes that could be visually scored in the first 5 days of embryonic development. We found six recessive embryonic lethal mutations, a frequency of about one mutation per 80–100 insertions (Allende *et al.*, 1996; Becker *et al.*, 1998; Gaiano *et al.*, 1996b; Young *et al.*, 2002). We also found one viable dominant insertional mutation (Kawakami *et al.*, 2000). Although this rate was too inefficient to conduct a large-scale screen by breeding one insertion at a time, by using the ability of founders to transmit multiple insertions to individual F1 progeny an average of about 12 inserts can be screened per family, allowing the recovery of about one insertional mutation per seven families screened (Amsterdam *et al.*, 1999; Amsterdam, unpublished data). This is only 7- to 10-fold lower than the frequency observed in analogously performed (three-generation diploid) ENU screens (Driever *et al.*, 1996; Haffter *et al.*, 1996; Mullins *et al.*, 1994; Solnica-Krezel *et al.*, 1994). The strategy to produce, select, and breed the fish for such an insertional mutagenesis screen is outlined in this section.

### **A. Making Founder Fish That Transmit Proviral Inserts at High Frequency to Their F1 Progeny**


Founders are produced by injecting late-blastula-stage (512–2000 cells) embryos. Virus must be injected into the space between the cells, and blastula-stage embryos ideally accommodate the injected fluid. At this time, there are four primordial germ cells, and these cells divide two or three times over the course of the infection (Yoon *et al.*, 1997). Thus, the injected embryos grow up to be founder fish (F0) with mosaic germ lines. With very good viral stocks, individual founders can contain 25–30 different insertions in their germ lines, with any given insertion present in 3–20% of the gametes (Amsterdam, unpublished data; Chen *et al.*, 2002). Individual F1 fish can inherit up to 10 different insertions, and when founders are bred to each other F1 fish can be found with up to 20 different insertions. F1 fish are not mosaic and transmit all their insertions in a Mendelian fashion.

Because the efficiency of the screen relies on the generation of F1 fish with a high number of inserts, it is essential to perform quality control assays on the viral stocks and founder injections before raising and breeding the founders. For every batch of injected embryos, several embryos are sacrificed for DNA preparation at 48 h postinjection and subjected to quantitative Southern analysis or real-time polymerase chain reaction (PCR) to determine the average number of insertions per cell in the entire infected embryo. This number is called the embryo assay value (EAV; Amsterdam *et al.*, 1999). In our experience, if the average EAV is above 15 and does not vary much among the individual analyzed embryos, the rest of the founders from that injection session transmit inserts at the rates mentioned previously. Batches with average EAV below 15 transmit somewhat fewer inserts, and usually have greater founder-to-founder variation, and those with average EAV below 5 are quite inconsistent in transmitting multiple inserts to their progeny.

### **B. Breeding and Screening for Mutations**

The breeding scheme for a diploid F3 insertional mutagenesis screen is outlined in Fig. 1. In essence, the goal is to create families with a large number of independent insertions that can be screened simultaneously. This is achieved by selecting and breeding F1 fish that inherit the most inserts from the mosaic founders.

Founder fish can be bred to each other or outcrossed to nontransgenic fish. For reasons that remain unclear, a majority of injected fish grow up to be males; thus, it is most efficient to outcross the best male F0 fish (those from batches with the highest EAV) and inbreed the rest. F1 families of 30 fish are raised, and at 6 weeks of age the fish are fin clipped for DNA preparation and analysis by quantitative Southern or real-time PCR to determine which fish harbor the most insertions. Keeping up to the three top fish per family with at least five inserts strikes a balance between throwing away too many inserts (if fewer fish were kept) and keeping too many ‘repeat inserts’ (i.e., the same insert inherited by sibling F1 fish). The repeat insert rate is quite low if only three fish are kept, as the average mosaicism



1. Inject pseudotyped virus into blastula-stage embryos.

2. Raise and inbreed founders.

3. Raise F1 pools and isolate tail DNA from individual fish. Use quantitative PCR to identify fish with the most insertions.

4. Cross multi-insert F1 fish to each other to generate F2 pools with 10–20 insertions, in which half of the fish have any given insertion.

5. Screen at least six crosses within each F2 pool. In this manner each insertion will be homozygosed in at least one of the crosses.

Fig. 1 Insertional mutagenesis breeding scheme.

(i.e., proportion of F1 inheriting a given insert) is about 8%. In our screen, only 3% of the recovered mutations have been caused by reisolating such repeat inserts.

The selected multiinsert F1 fish are pooled together and eventually bred to make F2 families that harbor at least 10 different independently segregating inserts, and in which each insert is present in half the fish. Multiple sibcrosses are then conducted between the F2 fish; because half the fish have any given insert, including one causing a mutation, should be homozygosed in one quarter of the

crosses. On average, six crosses will homozygose 83% of the inserts in the family and ten crosses will screen 95% of them. Every F3 clutch from each F2 family is screened for a phenotype in one quarter of the embryos. In our screen, embryos were scored for any morphological defect visible in a dissecting microscope at 1, 2, and 5 days post fertilization (dpf), as well as for defects in motility and touch response. One aid to screening is that more than 98% of these mutants fail to inflate their swim bladders by 5 dpf; because this is such a highly visible structure, a quick screen for clutches in which one quarter of the embryos fail to inflate their swim bladder often signals the presence of a mutation.

---

---


---

### III. Cloning the Mutated Genes

#### A. Identifying the Mutagenic Insert

The great advantage to using insertional mutagenesis over chemical mutagenesis is that the mutagenic insertion provides a molecular tag that can be used to identify the disrupted gene. However, because the mutagenesis screen described uses multiple insertions to increase the rate of recovery of mutations, the first step after identifying a mutation is to determine which (if any) insertion appears to be responsible for the mutation. DNA is prepared from the tails of the parents of all of the crosses from the F2 family, and, using Southern analysis to distinguish the different insertions, one looks for an insertion that segregates with the phenotype (Fig. 2A). A linked insert (represented by a band of a specific size) will be shared by both parents of every cross that had the phenotype and be in only one or neither of the parents of every cross that lacked the phenotype. In addition, DNA prepared from the mutant embryos is subjected to the same analysis; an unlinked insert would be in only three quarters of the mutant embryos, but a linked insert must be present in all of them (Fig. 2B).

It is possible that no insert appears linked to the phenotype; in our screen, we found that about one quarter of the mutants recovered were not linked to a detectable insertion. In addition, it is important to note that the identification of an insertion initially linked to the phenotype is not proof that the identified insert is *tightly* linked to the mutation; it is merely a way to either identify the insertion that is a *candidate* for causing the mutation or to conclude that the mutation is not linked to any insert if no insert meets the criteria. This is because recombination rates in the male germline are much lower than in the female germline (Johnson, personal communication; Amsterdam, unpublished data); thus, an insert inherited from an F1 male that is merely on the same chromosome as a noninsertional mutation will often meet the previously mentioned criteria. The mutation and the insert will not have segregated in the F2 generation, and because the mutant F3 embryos must inherit the mutant locus from both parents, even if there is recombination in the female germ line all the mutant embryos will receive the insert from their father. Thus, additional linkage experiments that can distinguish



**Fig. 2** Identification of the mutagenic insert. (A) Southern analysis of DNA prepared from tail fins of F2 fish: the arrow indicates an insert that is homozygosed in phenotypic pairs but not any of the wild-type pairs. (B) Southern analysis of DNA from individual mutant embryos from the second phenotypic pair in (A) the arrow indicates that the same insert is also present in all the mutant embryos.

heterozygosity from homozygosity for the insert are required, but it is not possible to perform these until genomic DNA flanking the candidate insert is cloned.

Sometimes more than one insert meets the previously mentioned criteria, and thus more than one are candidates to have caused the mutant phenotype. This can be for one of several reasons. First, if more than one insert in the family is on the same chromosome, for the reasons described previously they might fail to segregate from each other. Often this can be resolved by outcrossing a female carrier and repeating the analysis in the next generation, either by further random sib crosses followed by molecular analysis or by using Southern analysis first to identify fish with one or the other insertion and then performing test crosses. Another possibility is that multiple copies of the virus have integrated in tandem, which happens about 3–4% of the time. Usually when this happens, there is a higher-intensity provirus-sized band (if the enzyme used cuts the insert only once) in addition to the true junction fragment band. Finally, there might be too many inserts in the family to accurately distinguish all the inserts (more than 15–20), and